Objective. To assess the predictive value of the b3-tubuline expression by tumor cells in case of diffuse large-cell lymphoma (DLCL, nos) and of Burkitt’s lymphoma.
Materials and methods. The b3-tubuline expression by tumor cells (DLCL, nos — 21 patients, Burkitt’s lymphoma — 9 patients) was determined immunohistochemically. While assessing the immunohistochemical staining outcomes the percentage of the positively stained cells and their mutual arrangement character were considered.
Results. b3-tubuline expression by tumor cells was identified in 72.7% (8 of 11) of the DLCL patients demonstrating the GCB immune phenotype whereas only 20% (2 of 10) of tumors having non-GCB immune phenotype were stained positively with b3-tubuline (c2=5.838; р=0.016). The tumor-specific survival median in the b3-tubuline positive patients was 21.7 [7.3—26.5] months, in the b3-tubuline negative patients — 8.9 [7.2—41.5] months (p=0.049). Each Burkitt’s lymphoma studies had the b3-tubuline positive status making those patients stratification by the factor not possible.
Conclusion. The b3-tubuline expression by tumor cells in case of DLCL, nos and Burkitt’s lymphoma evidences of the tumor origin from the central blasts. In case of DLCL, nos the b3-tubuline expression may be used as an optional marker of the tumor reference to the GCB subtype characterized by a more favorable clinical course.
Автор(ы): D. A. Davydov, K. G. Ruksha, T. M. Doroshenko, A. S. Portyanko, E. D. Cherstvy